Melanoma Research

Melanoma Research

Research into melanoma at Penn State Cancer Institute is conducted by the melanoma and skin cancer team. See current clinical trials and members of that team here.

Clinical Trials

Umbrella Long-term Follow-up Protocol
A Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors
Development and Validation of a Gene Expression Assay to Predict the Risk of Metastatic Disease in Malignant Cutaneous Melanoma
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma
The Collection of Blood, Tissue and Phenotypic Data in Patients Diagnosed with Skin Cancers and Subsequent Metastases for Inclusion in a Repository and Use in Outcome Studies
Atypical Spotzoid Melanocytic Tumors: An Institutional Review of Outcomes for an Effective Treatment
Application for Discarded Tissue From Surgery For Research Use
Infrared Lymphangiography as a Method of Sentinel Node Identification
Pathology Characteristics of Cutaneous Melanoma in Females and Association with UV Exposure
Definition of Somatic Variants Corresponding to Immune Targets in Patients with Metastatic Melanoma
A Retrospective Evaluation to Understand how â-adrenergic Antagonism Impacts the Progression of Melanoma and the Efficacy of Standard Treatments Intended to Eliminate the Cancer
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Disease Team Members

Research into melanoma at Penn State Cancer Institute is conducted by the melanoma and skin cancer team. See current clinical trials and members of that team here.
Umbrella Long-term Follow-up Protocol
A Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors
Development and Validation of a Gene Expression Assay to Predict the Risk of Metastatic Disease in Malignant Cutaneous Melanoma
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma
The Collection of Blood, Tissue and Phenotypic Data in Patients Diagnosed with Skin Cancers and Subsequent Metastases for Inclusion in a Repository and Use in Outcome Studies
Atypical Spotzoid Melanocytic Tumors: An Institutional Review of Outcomes for an Effective Treatment
Application for Discarded Tissue From Surgery For Research Use
Infrared Lymphangiography as a Method of Sentinel Node Identification
Pathology Characteristics of Cutaneous Melanoma in Females and Association with UV Exposure
Definition of Somatic Variants Corresponding to Immune Targets in Patients with Metastatic Melanoma
A Retrospective Evaluation to Understand how â-adrenergic Antagonism Impacts the Progression of Melanoma and the Efficacy of Standard Treatments Intended to Eliminate the Cancer
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)